Final results from the large sunitinib global expanded-access trial
We report final results with extended follow-up from a global, expanded-access trial that pre-regulatory approval provided sunitinib to metastatic renal cell carcinoma (mRCC) patients, ineligible for registration-directed trials.06/19/2015
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Kidney Cancer | Renal Cell Carcinoma | Urology & Nephrology